Biodesix (NASDAQ:BDSX – Get Free Report) and Beauty Health (NASDAQ:SKIN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.
Analyst Recommendations
This is a summary of current ratings and price targets for Biodesix and Beauty Health, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biodesix | 1 | 1 | 4 | 0 | 2.50 |
| Beauty Health | 2 | 4 | 1 | 0 | 1.86 |
Biodesix currently has a consensus price target of $32.50, indicating a potential upside of 192.27%. Beauty Health has a consensus price target of $2.40, indicating a potential upside of 58.42%. Given Biodesix’s stronger consensus rating and higher possible upside, analysts clearly believe Biodesix is more favorable than Beauty Health.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biodesix | $71.32 million | 1.24 | -$42.93 million | ($5.56) | -2.00 |
| Beauty Health | $334.30 million | 0.58 | -$29.10 million | ($0.22) | -6.89 |
Beauty Health has higher revenue and earnings than Biodesix. Beauty Health is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Biodesix has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Beauty Health has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500.
Insider & Institutional Ownership
21.0% of Biodesix shares are held by institutional investors. Comparatively, 93.3% of Beauty Health shares are held by institutional investors. 30.1% of Biodesix shares are held by company insiders. Comparatively, 41.0% of Beauty Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Biodesix and Beauty Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biodesix | -49.31% | -504.41% | -43.94% |
| Beauty Health | -3.87% | -19.70% | -1.97% |
Summary
Beauty Health beats Biodesix on 9 of the 14 factors compared between the two stocks.
About Biodesix
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
About Beauty Health
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.
